Companion Diagnostics and Predictive Biomarkers for PD-1/PD-L1 Immune Checkpoint Inhibitors Therapy in Malignant Melanoma

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Nov 12

PMID 39530091

Authors

Zeping Wang

Xiaojing Zou

Haiyan Wang

Zhihui Hao

Gebin Li

Shuaiyu Wang

Affiliations

Soon will be listed here.

Abstract

Programmed cell death receptor 1 (PD-1), when bound to the ligand programmed death-ligand 1 (PD-L1), can suppress cellular immunity and play a critical role in the initiation and development of cancer. Immune drugs targeting these two sites have been developed for different cancers, including malignant melanoma. The accompanying diagnostic method has been approved by the FDA to guide patient medication. However, the method of immunohistochemical staining, which varies widely due to the antibody and staining cut-off values, has certain limitations in application and does not benefit all patients. Increasing researches begin to focus on new biomarkers to improve objective response rates and survival in cancer patients. In this article, we enumerated three major groups, including tumour microenvironment, peripheral circulation, and gene mutation, which covered the current main research directions. In the future, we hope those biomarkers may be used to guide the treatment of patients with malignant melanoma.

References

LaFleur M, Muroyama Y, Drake C, Sharpe A . Inhibitors of the PD-1 Pathway in Tumor Therapy. J Immunol. 2018; 200(2):375-383. PMC: 5924692. DOI: 10.4049/jimmunol.1701044. View

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

Hui R, Garon E, Goldman J, Leighl N, Hellmann M, Patnaik A . Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Ann Oncol. 2017; 28(4):874-881. PMC: 6354672. DOI: 10.1093/annonc/mdx008. View

Dong H, Strome S, Salomao D, Tamura H, Hirano F, Flies D . Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002; 8(8):793-800. DOI: 10.1038/nm730. View

Hiratsuka S, Watanabe A, Aburatani H, Maru Y . Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol. 2006; 8(12):1369-75. DOI: 10.1038/ncb1507. View

Amaral T, Pop O, Chatziioannou E, Sinnberg T, Niessner H, Zhao J . EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy. J Am Acad Dermatol. 2023; 89(5):1072-1074. DOI: 10.1016/j.jaad.2023.06.057. View

Yun S, Park Y, Moon S, Ahn S, Lee K, Park H . Clinicopathological and prognostic significance of programmed death ligand 1 expression in Korean melanoma patients. J Cancer. 2019; 10(13):3070-3078. PMC: 6590033. DOI: 10.7150/jca.30573. View

Serrati S, Guida M, Di Fonte R, De Summa S, Strippoli S, Iacobazzi R . Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma. Mol Cancer. 2022; 21(1):20. PMC: 8764806. DOI: 10.1186/s12943-021-01490-9. View

Olson D, Eroglu Z, Brockstein B, Poklepovic A, Bajaj M, Babu S . Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. J Clin Oncol. 2021; 39(24):2647-2655. PMC: 8376314. DOI: 10.1200/JCO.21.00079. View

10.

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman D . IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017; 127(8):2930-2940. PMC: 5531419. DOI: 10.1172/JCI91190. View

11.

Koyama S, Akbay E, Li Y, Aref A, Skoulidis F, Herter-Sprie G . STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Res. 2016; 76(5):999-1008. PMC: 4775354. DOI: 10.1158/0008-5472.CAN-15-1439. View

12.

Xia J, Huang R, Chen Y, Liu Y, Wang J, Yan X . Profiles of serum soluble programmed death-1 and programmed death-ligand 1 levels in chronic hepatitis B virus-infected patients with different disease phases and after anti-viral treatment. Aliment Pharmacol Ther. 2020; 51(11):1180-1187. DOI: 10.1111/apt.15732. View

13.

Dronca R, Liu X, Harrington S, Chen L, Cao S, Kottschade L . T cell Bim levels reflect responses to anti-PD-1 cancer therapy. JCI Insight. 2016; 1(6). PMC: 4863706. DOI: 10.1172/jci.insight.86014. View

14.

Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S . Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020; 395(10240):1835-1844. DOI: 10.1016/S0140-6736(20)30934-X. View

15.

Teng M, Ngiow S, Ribas A, Smyth M . Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res. 2015; 75(11):2139-45. PMC: 4452411. DOI: 10.1158/0008-5472.CAN-15-0255. View

16.

Gandini S, Zanna I, De Angelis S, Palli D, Raimondi S, Ribero S . TERT promoter mutations and melanoma survival: A comprehensive literature review and meta-analysis. Crit Rev Oncol Hematol. 2021; 160:103288. DOI: 10.1016/j.critrevonc.2021.103288. View

17.

Hirsch F, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K . PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol. 2016; 12(2):208-222. DOI: 10.1016/j.jtho.2016.11.2228. View

18.

Weide B, Martens A, Hassel J, Berking C, Postow M, Bisschop K . Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. Clin Cancer Res. 2016; 22(22):5487-5496. PMC: 5572569. DOI: 10.1158/1078-0432.CCR-16-0127. View

19.

Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N . Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002; 99(19):12293-7. PMC: 129438. DOI: 10.1073/pnas.192461099. View

20.

Zak K, Grudnik P, Magiera K, Domling A, Dubin G, Holak T . Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2. Structure. 2017; 25(8):1163-1174. DOI: 10.1016/j.str.2017.06.011. View